Claims for Patent: 8,398,967

Summary for Patent: 8,398,967

Title:	Particle formulations for use in pharmaceutical compositions
Abstract:	A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.
Inventor(s):	Eliaz; Rom Ezer (San Rafael, CA), Zhang; Yuanpeng (Cupertino, CA), Rohloff; Catherine Manya (Los Altos, CA), Weeks; Eric William (Hayward, CA), Junnarkar; Gunjan (Palo Alto, CA)
Assignee:	Intarcia Therapeutics, Inc. (Hayward, CA)
Application Number:	13/091,970
Patent Claims:	1. A particle formulation for use in a pharmaceutical composition comprising a protein or peptide, sucrose, methionine, and citrate buffer. 2. The particle formulation of claim 1, wherein said protein or peptide is selected from the group consisting of interferon, erythropoietin, human growth hormone, granulocyte macrophage colony stimulating factor, human growth hormone releasing hormone, insulin, infliximab, and glucagon-like peptide-1. 3. The particle formulation of claim 2, wherein the protein or peptide is glucagon-like peptide-1. 4. The particle formulation of claim 2, wherein the protein or peptide is an interferon. 5. The particle formulation of claim 4, wherein the interferon is selected from the group consisting of omega-interferon, alpha-interferon, beta-interferon, and gamma-interferon. 6. The particle formulation of claim 1, wherein the particle formulation comprises the protein or peptide, sucrose, methionine, and citrate buffer in a weight ratio of 1:2:1:2.15. 7. The particle formulation of claim 1, wherein particles of the formulation are made by spray-drying, lyophilization, or supercritical fluid processing. 8. The particle formulation of claim 1, wherein the particle formulation comprises spray-dried particles. 9. The particle formulation of claim 8, wherein the spray-dried particles comprise particles of about 1 .mu.m to about 10 .mu.m in diameter. 10. An implantable osmotic delivery device, comprising: a capsule having a first chamber containing a viscous liquid pharmaceutical composition and a second chamber containing an osmotic agent, the first chamber having an opening through which the pharmaceutical composition can be delivered from the first chamber to a location external of the first chamber; a movable piston positioned in the capsule between the first chamber and the second chamber; a wall of the second chamber comprising a fluid permeable membrane portion; and an incompressible fluid additive located within the second chamber and substantially surrounding the osmotic agent; wherein the viscous liquid pharmaceutical composition comprises the particle formulation of claim 1 dispersed in a suspending vehicle, and the suspending vehicle comprising a solvent selected from the group consisting of benzyl benzoate, lauryl lactate, and lauryl alcohol. 11. The implantable osmotic delivery device of claim 10, wherein the solvent is benzyl benzoate. 12. The implantable osmotic delivery device of claim 10, wherein the solvent is lauryl lactate. 13. The implantable osmotic delivery device of claim 10, wherein the solvent is lauryl alcohol. 14. The implantable osmotic delivery device of claim 10, wherein the suspending vehicle further comprises a lipid. 15. The implantable osmotic delivery device of claim 10, wherein the particle formulation comprises the protein or peptide, sucrose, methionine, and citrate buffer in a weight ratio of 1:2:1:2.15. 16. The implantable osmotic delivery device of claim 10, wherein particles of the formulation are made by spray-drying, lyophilization, or supercritical fluid processing. 17. The implantable osmotic delivery device of claim 10, wherein the particle formulation comprises spray-dried particles. 18. The implantable osmotic delivery device of claim 17, wherein the spray-dried particles comprise particles of about 1 .mu.m to about 10 .mu.m in diameter. 19. The implantable osmotic delivery device of claim 10, wherein the osmotic agent is a tablet comprising NaCl. 20. The implantable osmotic delivery device of claim 19, wherein the incompressible fluid additive comprises PEG.

Details for Patent 8,398,967

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2039-02-26